Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of prophylactic recombinant human thrombopoietin during concurrent chemoradiotherapy for cervical cancer
ChiCTR1800017093Phase 2Not yet recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Aug 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of recombinant human thrombopoietin in Thrombocytopenia (2 arms), sponsored by Cancer Center of Guangzhou Medical University. Primary endpoint: Platelet nadir. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR1800017093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017093.